vs
Side-by-side financial comparison of BeOne Medicines Ltd. (ONC) and Roper Technologies (ROP). Click either name above to swap in a different company.
Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.5B, roughly 1.4× BeOne Medicines Ltd.). Roper Technologies runs the higher net margin — 15.8% vs 4.4%, a 11.4% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 11.3%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $379.8M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 10.5%).
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
ONC vs ROP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.1B |
| Net Profit | $66.5M | $331.0M |
| Gross Margin | 90.5% | 69.4% |
| Operating Margin | 12.4% | 27.2% |
| Net Margin | 4.4% | 15.8% |
| Revenue YoY | 32.8% | 11.3% |
| Net Profit YoY | 143.8% | 53.7% |
| EPS (diluted) | $0.05 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.5B | $2.1B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.1B | $1.9B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $1.0B | $1.8B | ||
| Q2 24 | $929.2M | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $66.5M | $428.4M | ||
| Q3 25 | $124.8M | $398.5M | ||
| Q2 25 | $94.3M | $378.3M | ||
| Q1 25 | $1.3M | $331.1M | ||
| Q4 24 | $-151.9M | $462.3M | ||
| Q3 24 | $-121.3M | $367.9M | ||
| Q2 24 | $-120.4M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | 90.5% | 69.5% | ||
| Q3 25 | 86.1% | 69.5% | ||
| Q2 25 | 87.5% | 69.2% | ||
| Q1 25 | 85.2% | 68.7% | ||
| Q4 24 | 85.8% | 68.3% | ||
| Q3 24 | 83.0% | 69.2% | ||
| Q2 24 | 85.1% | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | 12.4% | 28.6% | ||
| Q3 25 | 11.5% | 28.4% | ||
| Q2 25 | 6.7% | 28.2% | ||
| Q1 25 | 1.0% | 27.9% | ||
| Q4 24 | -7.0% | 28.0% | ||
| Q3 24 | -12.0% | 28.1% | ||
| Q2 24 | -11.5% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 4.4% | 20.8% | ||
| Q3 25 | 8.8% | 19.8% | ||
| Q2 25 | 7.2% | 19.5% | ||
| Q1 25 | 0.1% | 17.6% | ||
| Q4 24 | -13.5% | 24.6% | ||
| Q3 24 | -12.1% | 20.8% | ||
| Q2 24 | -13.0% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.05 | $3.97 | ||
| Q3 25 | $0.08 | $3.68 | ||
| Q2 25 | $0.06 | $3.49 | ||
| Q1 25 | $0.00 | $3.06 | ||
| Q4 24 | $-0.10 | $4.29 | ||
| Q3 24 | $-0.09 | $3.40 | ||
| Q2 24 | $-0.09 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.5B | $382.9M |
| Total DebtLower is stronger | $836.4M | $9.7B |
| Stockholders' EquityBook value | $4.4B | $18.8B |
| Total Assets | $8.2B | $34.6B |
| Debt / EquityLower = less leverage | 0.19× | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $4.5B | $297.4M | ||
| Q3 25 | $4.0B | $320.0M | ||
| Q2 25 | $2.8B | $242.4M | ||
| Q1 25 | $2.5B | $372.8M | ||
| Q4 24 | $2.6B | $188.2M | ||
| Q3 24 | $2.7B | $269.6M | ||
| Q2 24 | $2.6B | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | $836.4M | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $4.4B | $19.9B | ||
| Q3 25 | $4.1B | $20.0B | ||
| Q2 25 | $3.8B | $19.6B | ||
| Q1 25 | $3.5B | $19.2B | ||
| Q4 24 | $3.3B | $18.9B | ||
| Q3 24 | $3.4B | $18.5B | ||
| Q2 24 | $3.4B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $8.2B | $34.6B | ||
| Q3 25 | $7.6B | $34.6B | ||
| Q2 25 | $6.3B | $33.2B | ||
| Q1 25 | $5.8B | $31.4B | ||
| Q4 24 | $5.9B | $31.3B | ||
| Q3 24 | $5.8B | $31.6B | ||
| Q2 24 | $5.7B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.19× | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $417.3M | — |
| Free Cash FlowOCF − Capex | $379.8M | $507.0M |
| FCF MarginFCF / Revenue | 25.4% | 24.2% |
| Capex IntensityCapex / Revenue | 2.5% | 0.5% |
| Cash ConversionOCF / Net Profit | 6.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $941.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $417.3M | $738.0M | ||
| Q3 25 | $402.6M | $869.5M | ||
| Q2 25 | $263.6M | $404.1M | ||
| Q1 25 | $44.1M | $528.7M | ||
| Q4 24 | $75.2M | $722.2M | ||
| Q3 24 | $188.4M | $755.4M | ||
| Q2 24 | $-95.6M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $379.8M | — | ||
| Q3 25 | $354.5M | — | ||
| Q2 25 | $219.8M | — | ||
| Q1 25 | $-12.3M | — | ||
| Q4 24 | $-17.3M | — | ||
| Q3 24 | $54.7M | — | ||
| Q2 24 | $-205.5M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 25.4% | — | ||
| Q3 25 | 25.1% | — | ||
| Q2 25 | 16.7% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | -22.1% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 2.5% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 8.2% | — | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 11.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.28× | 1.72× | ||
| Q3 25 | 3.22× | 2.18× | ||
| Q2 25 | 2.79× | 1.07× | ||
| Q1 25 | 34.71× | 1.60× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
